CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
leteprinim potassium (Neotrofin)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00041795
NCT00041795Phase 2Completed
CompareCT.gov

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Neotrofin to Treat Patients With Sensory or Motor Neuropathy Caused by Chemotherapy for Cancer

NeoTherapeutics·interventional·Posted Jul 19, 2002·Updated Jun 24, 2005

In Brief

A Phase 2 clinical trial evaluating leteprinim potassium (Neotrofin) for Peripheral Nervous System Diseases and Chemotherapy-Induced Peripheral Neuropathy. Completed, across 6 sites.

Detailed Summary

This study will assess the safety and efficacy of Neotrofin in treating the peripheral neuropathy that results from chemotherapy for cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Nervous System Diseases, Chemotherapy-Induced Peripheral Neuropathy
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 19, 2002
Enrollment StartJan 1, 2002
TodayJul 2, 2026
Posted 24.0 years ago

Interventions

leteprinim potassium (Neotrofin)drug